Showing results (1001-1010 of 1,035) with videos related to
Sort By:
Pageof 104
Lancet (London, England)|June 29, 2020
Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trialRaj R Makkar, Wen Cheng, Ron Waksman, et al.Physical Review Letters|July 31, 2025
Monolayer Control of Spin-Charge Conversion in van der Waals HeterostructuresKhasan Abdukayumov, Oliver Paull, Martin Mičica, et al.Journal of the American College of Cardiology|June 16, 2026
10-Year Randomized Outcomes of Transcatheter or Surgical Aortic Valve Replacement in Intermediate-Risk Aortic StenosisVinod H Thourani, Philipp von Stein, Michael J Mack, et al.Journal of the American College of Cardiology|February 27, 2016
Outcomes in Patients With Transcatheter Aortic Valve Replacement and Left Main Stenting: The TAVR-LM RegistryTarun Chakravarty, Rahul Sharma, Yigal Abramowitz, et al.Journal of the American College of Cardiology|September 13, 2023
Comprehensive Management of ANOCA, Part 2-Program Development, Treatment, and Research Initiatives: JACC State-of-the-Art ReviewNathaniel R Smilowitz, Megha Prasad, R Jay Widmer, et al.Texas Heart Institute Journal|September 17, 2010
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.American Heart Journal|August 25, 2009
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarctionJay H Traverse, Timothy D Henry, Douglas E Vaughan, et al.Circulation Research|August 20, 2014
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomesChristopher R Cogle, Elizabeth Wise, Amy M Meacham, et al.Journal of the American College of Cardiology|September 13, 2023
Comprehensive Management of ANOCA, Part 1-Definition, Patient Population, and Diagnosis: JACC State-of-the-Art ReviewBruce A Samuels, Samit M Shah, R Jay Widmer, et al.Circulation Research|February 21, 2015
Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient dataMariann Gyöngyösi, Wojciech Wojakowski, Patricia Lemarchand, et al.Pageof 104